文献速递治疗药物监测与药物基因组学特殊人群用药

基于模拟的crovalimab个体化给药在PNH中的探索:便利性与成本效益潜力

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency.
PubMed 文献 · Br J Clin Pharmacol · 2026-06-14

该研究利用已上市产品群体药代动力学模型开展临床试验模拟,在初治PNH患者中比较标准、按体重及TDM引导的crovalimab给药方案52周。结果显示标准方案维持期浓度多高于治疗目标且变异大,按体重给药降低变异,TDM引导进一步降低变异并使24%患者给药间隔延长至平均5.0周而暴露与标准方案相当。

要点

  • 标准crovalimab维持期暴露多高于药效目标且个体间变异明显。
  • 按体重给药可降低暴露变异,TDM引导可进一步降低变异。
  • TDM引导下24%患者给药间隔可延长至平均5.0周且暴露与标准方案相当。

核心结论

  • crovalimab个体化给药可降低暴露变异并允许减少给药频率,支持更灵活、具成本效益且以患者为中心的治疗方案可行性。

研究设计与样本

  • 基于上市许可持有人开发的群体药代动力学模型开展临床试验模拟,在初治PNH患者中比较标准、按体重和TDM引导方案52周。

主要发现

  • 维持期crovalimab浓度总体高于治疗目标且存在明显变异。
  • 按体重给药降低暴露变异,TDM引导给药进一步降低变异。
  • TDM引导下24%患者给药间隔延长至平均5.0周,暴露与标准方案相当。

关键数值与推荐

  • TDM引导方案使24%患者给药间隔延长至平均5.0周,同时维持与标准方案相当的暴露。

临床怎么用

  • 临床可考虑按体重或TDM引导调整crovalimab给药,以降低暴露变异并个体化延长给药间隔。

局限性

  • 研究为基于群体药代动力学模型的临床试验模拟,非真实世界临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5-inhibitor, is approved for PNH and can be self-administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5-inhibitors. Since exposure often exceeds pharmacokinetic targets and varies with body weight, we aimed to explored individualized dosing of crovalimab using clinical trial simulations to optimize therapy. METHODS: We compared standard, weight-based and therapeutic drug monitoring (TDM)-guided regimens in treatment-naïve PNH patients over 52 weeks by means of clinical trial simulations based on the population pharmacokinetic model developed by the market authorization holder. RESULTS: Maintenance-phase crovalimab concentrations were generally supratherapeutic with substantial variability. Weight-based dosing reduced this variability, while TDM-guided dosing further minimized it and allowed dose intervals to be prolonged in 24% of patients to a mean of 5.0 weeks, while maintaining exposure comparable to the standard regimen. CONCLUSION: Individualized dosing of crovalimab may reduce exposure variability and enable less frequent dosing, supporting the feasibility of more flexible cost-effective and patient-tailored treatment regimens.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ter Avest M, Koele SE, van de Kar NCAJ, et al. Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency. Br J Clin Pharmacol. 2026. PMID: 42289378. doi:10.1002/bcp.70651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。